Yanagawa H, Takishita Y, Bando H, Sumitani H, Okada S
Department of Respiratory Diseases, Tokushima Prefectural Central Hospital, Japan.
Anticancer Res. 1996 Jan-Feb;16(1):533-5.
In the present study, we investigated the pharmacology of carboplatin in two patients with chronic renal failure undergoing hemodialysis. In Case 1, squamous cell carcinoma of the epipharynx was treated with 265 mg/m2 of carboplatin alone. In Case 2, adenocarcinoma of the lung was treated with 300 mg/m2 of carboplatin in combination with 50 mg/m2 of etoposide. All agents were injected intravenously. Hemodialysis was initiated 30 minutes after carboplatin administration. Most platinum was excluded by hemodialysis in a pattern similar to that in patients with normal renal function. These observations suggest that carboplatin-based chemotherapy can be considered as a treatment modality for malignant neoplasia in patients with chronic renal failure undergoing hemodialysis.
